Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label repeat-dose escalation pharmacokinetic study of ropinirole prolonged release 12 mg in Parkinson's disease
2006-006209-94Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ropinirole prolonged release in Parkinson's disease (PD), sponsored by GSK. Primary endpoint: Ropinirole AUC (0-24ss). Started Jan 2007; status: completed.
02
Drugs
ropinirole prolonged release
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-006209-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006209-94.